

Loncastuximab in high-risk and heavily pretreated relapsed/refractory diffuse large B-cell lymphoma: a real-world analysis from 21 US centers

Viktoriya Zelikson,¹ Ashwath Gurumurthi,^{2,3} Yazeed Sawalha,⁴ Kaitlin Annunzio,⁴ Aditi Saha,⁵ Ning Dong,⁵ David Qualls,⁶ Behzad Amoozgar,⁷ Brad Kahl,⁷ John Baird,⁸ Pavan Challa,⁹ Scott F. Huntington,⁹ Jennifer Santos,¹⁰ Steven Bair,¹⁰ Mayur Narkhede,¹¹ Shuning Li,¹² Zachary Frosch,¹² Carrie Ho,¹³ Stephen D. Smith,¹³ Allison Winter,¹⁴ Daniel Landsburg,¹⁵ Fateeha Furqan,¹⁶ Mehdi Hamadani,¹⁶ Katelin Baird,¹⁷ Jason Romancik,¹⁷ Hanan Alharthy,¹⁸ Jennie Law,¹⁸ Leyla Bojanini,¹⁹ Ranjana Advani,¹⁹ Boyu Hu,²⁰ Patrick Connor Johnson,²¹ Natalie S. Grover,²² Mwanasha Merril,⁶ Jennifer L. Crombie,⁶ Nazila Shafagati,²³ Cole Sterling,²³ Loretta J. Nastoupil,² Narendranath Epperla⁴ and Emily C. Ayers¹

¹University of Virginia Health System, Charlottesville, VA; ²MD Anderson Cancer Center, Houston, TX; ³Memorial Sloan Kettering Cancer Center, New York, NY; ⁴The Ohio State University Comprehensive Cancer Center, Columbus, OH; ⁵Moffit Cancer Center, Tampa, FL; ⁶Dana-Farber Cancer Institute, Boston, MA; ⁷Siteman Cancer Center, Washington University of St Louis, St. Louis, MO; ⁸City of Hope Cancer Center, Los Angeles, CA; ⁹Yale University, Yale Cancer Center, New Haven, CT; ¹⁰University of Colorado Cancer Center, Anschutz Medical Campus, Denver, CO; ¹¹University of Alabama, Birmingham, AL; ¹²Fox Chase Cancer Center, Philadelphia, PA; ¹³Fred Hutchinson Cancer Center, Seattle, WA; ¹⁴Cleveland Clinic Cancer Center, Cleveland, OH; ¹⁵Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; ¹⁶Medical College of Wisconsin, Milwaukee, WI; ¹⁷Winship Cancer Institute, Emory University, Atlanta, GA; ¹⁸University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD; ¹⁹Stanford Cancer Institute, Stanford, CA; ²⁰Hunstman Cancer Institute, University of Utah, Salt Lake City, UT; ²¹Mass General Cancer Care, Massachusetts General Hospital, Boston, MA; ²²Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC and ²³Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA

Correspondence: E.C. Ayers
Eca2t@uvahealth.org

Received: June 6, 2024.
Accepted: November 5, 2024.
Early view: November 14, 2024.

<https://doi.org/10.3324/haematol.2024.285977>

©2025 Ferrata Storti Foundation
Published under a CC BY-NC license 

Supplementary Table 1. Univariate and multivariate cox regression for OS and EFS

Factor	OS Univariate		OS Multivariate		EFS Univariate		EFS Multivariate	
	HR	p	HR	p	HR	p	HR	p
HGBL	1.92	0.001	2.71	<0.001	2.62	<0.001	2.08	0.003
nonGCB	0.73	0.10			0.68	0.04	0.82	0.34
Bulky disease	1.83	0.005	1.78	0.48	1.91	0.002	1.67	0.03
Elevated LDH	2.57	<0.001	1.62	0.05	2.27	<0.001	1.82	0.02
CR prior to Lonca	0.40	0.01	0.16	0.01	0.23	<0.001	0.16	0.01
CD19 status (+)	0.89	0.75			0.62	0.18		
Prior CAR T-cell	1.40	0.06			0.95	0.75		
Prior Tafasitamab	1.79	0.03	0.82	0.48	1.24	0.41		
# Prior therapies (>3)	1.28	0.27			1.20	0.42		
Age > 75	0.77	0.22			0.67	0.06		

OS: overall survival, EFS: event free survival, nonGCB: non-germinal B-cell